Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

3.37
+0.30009.77%
Post-market: 3.32-0.0500-1.48%19:44 EST
Volume:1.09M
Turnover:3.62M
Market Cap:288.44M
PE:-1.73
High:3.41
Open:3.13
Low:3.11
Close:3.07
52wk High:5.37
52wk Low:1.61
Shares:85.59M
Float Shares:45.15M
Volume Ratio:1.02
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9534
EPS(LYR):-1.3159
ROE:-78.24%
ROA:-42.99%
PB:2.07
PE(LYR):-2.56

Loading ...

Larimar Therapeutics Swaps Common Shares for Series A Convertible Preferred Stock in Private Placement

Reuters
·
Dec 17, 2025

Larimar Therapeutics Q3 Net Income USD -47.712 Million

Reuters
·
Nov 20, 2025

Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)

TIPRANKS
·
Nov 06, 2025

Larimar Therapeutics Q3 net loss widens

Reuters
·
Nov 05, 2025

BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million

Reuters
·
Nov 05, 2025

Larimar Therapeutics Q3 Basic EPS USD -0.61

THOMSON REUTERS
·
Nov 05, 2025

Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026

THOMSON REUTERS
·
Nov 05, 2025

Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Oct 24, 2025

Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)

TIPRANKS
·
Oct 08, 2025

Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?

Simply Wall St.
·
Oct 04, 2025

Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26

THOMSON REUTERS
·
Oct 02, 2025

Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)

TIPRANKS
·
Sep 30, 2025

U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech

Reuters
·
Sep 30, 2025

Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading

TIPRANKS
·
Sep 30, 2025

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
Sep 30, 2025

Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk

Dow Jones
·
Sep 30, 2025

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Benzinga_recent_news
·
Sep 29, 2025

BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug

Reuters
·
Sep 29, 2025

BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia

Reuters
·
Sep 29, 2025

Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug

THOMSON REUTERS
·
Sep 29, 2025